Treatment of benign prostatic hyperplasia and hypertension in elderly hypertensive patients

British Journal of Urology

Volumn 81, Issue SUPPL. 1, 1998, Pages 51-55

  Suzuki, H ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BUNAZOSIN; DOXAZOSIN; PRAZOSIN; TERAZOSIN;

ADULT; AGED; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SURVEILLANCE PROGRAM; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; JAPAN; MALE; MULTICENTER STUDY; NORMAL HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; REVIEW; VERTIGO;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; FEMALE; HUMANS; HYPERTENSION; MALE; MULTICENTER STUDIES; PRAZOSIN; PRODUCT SURVEILLANCE, POSTMARKETING; PROSTATIC HYPERPLASIA; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS;

EID: 0031857723     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1998.0810s1051.x     Document Type: Article

References (31)

1. Drizd T, Dannenberg A, Engel A. Blood pressure levels in persons 18-74 years of age in 1976-80, and trends in blood pressure from 1960 to 1980 in the United States. Vital Health Statistics 1986:11: DHHS Publication 86-1684
2. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 469-71
3. Drummond MF, McGuire AJ, Black NA, Petticrew M, McPherson CK. Economic burden of treatment of benign prostatic hyperplasia in the United Kingdom. Br J Urol 1993; 71: 290-6
4. Johannesson M, Borgquist L, Jonsson B. The costs of treating hypertension in Sweden. An empirical investigation in primary health care. Scand J Prim Health Care 1991; 9: 155-60
5. Wyss JM. The role of the sympathetic nervous system in hypertension. Curr OpinNephrolHypertens 1993: 2: 265-73
6. Forray C, Bard JA, Wetzel JM et al The a-adrenergic receptor that mediates smooth muscle contraction in the human prostate has the pharmacological properties of the cloned human ale subtype. Mol Pharmacol 1994; 45: 703-8
7. Wilde MI, Fitton A, Sorkin EM. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs Aging 1993; 3: 258-77
8. Kirby RS. Efficacy of doxazosin in normotensive and hypertensive patients with benign prostatic hyperplasia. ScandJUrol Nephrol 1995; 29: 29-33
9. Pool JL. Doxazosin. A new approach to hypertension and benign prostatic hyperplasia. Br J Clin Pract 1996; 50: 154-63
10. Thijs L, Fagard R. Lijnen P, Staessen J, Van Hoof R, Amery A. A meta-analysis of outcome trials in elderly hypertensives. J Hypertens 1992; 10: 1103-9
11. Chalmers J. Treatment guidelines in hypertension: current limitations and future solutions. J Hypertens 1996: 14: S3-8
12. Ogiwara T, Hiwada K, Matsuoka H et al. The Treatment Guidelines for The Elderly Subjects with Hypertension. Tokyo: Sentan Igakuku Sya: 1995 (In Japanese)
13. Collins R. Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2. short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827-8
14. Ogiware T. Characteristics and management of hypertension in the elderly. Jpn J Geriatr 1993; 30: 932-40
15. 5 Omae T, Fukiyama K, limura 0 et al. Efficacy of doxazosin on blood pressure in patients with essential hypertension. Randomized double-blind, single comparison study with prazosin. Igaku no Ayumi 1988; 146: 673-91 (In Japanese)
16. Kaneko Y. limura 0. Yoshinaga K et al. Efficacy of bunazosin-retard on blood pressure in patients with essential hypertension. Randomized double-blind, single comparison study with bunazosin. Kiso to Rinsyo 1992: 26: 5379-410 (In Japanese)
17. Kaneko Y. limura 0. Yasuda H et al. Efficacy of single administration of terazosin and its combined administration with diuretics on blood pressure in patients with essential hypertension. Randomized double-blind, single comparison study with prazosin. Rinsyo to Kenkyu 1988; 65: 242-77 (In Japanese)
18. Kawabe K. Ueno S, Takimoto S et al. Efficacy of YM617 on difficulties in urination in patients with benign prostatic hypertrophy. Hinyoki Geka 1991: 4: 233-42 (In Japanese)
19. Studer JA. Robert W. Antihypertensive therapy in the geriatric patient: II. A review of the alpha 1-adrenergic blocking agents. J Clin Pharmacol 1993; 33: 2-13
20. Stokes GS. Age-related effects of antihypertensive therapy with alpha-blockers. J Cardiovasc Pharmacol 1988: 12: S109-15
21. Cheung DG, Huffman CA, Ricci ST et al Mild hypertension in the elderly: A comparison of prazosin and enalapril. Am J Med 1989; 86: 87-90
22. Applegate VM. Hypertension in elderly patients. Ann Intern Med 1989: 110: 901-15
23. Young RA. Brogden RN. Doxazosin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in mild or moderate hypertension. Drags 1988; 35: 525-41
24. Mancia G, Seravalle G, Vailati S. Grassi G. Benefit vs. risk of calcium antagonists in hypertensive patients with concomitant risk factors. J Hypertens 1996: 14: S33-8
25. Hanssen L. The J-shaped curve and how far should blood pressure be lowered. In Laragh JH. Brenner BH, eds. Hypertension: Pathophysiology, Diagnosis ana Management, 2nd edn. New York: Raven Press. 1995: 2765-70
26. Michel MC, Buscher R. Kerker J, Kraneis H, Erbruger W, Brodde OE. a-adrenoceptor subtype affinities of drugs for the treatment of prostatic hypertrophy. Evidence for heterogeneity of chloroethylclonidine-resistant rat renal otadrenoceptors. Naunyn-Schmiedebergs Arch Pharmacol 1993: 348: 385-95
27. Foglar R. Shibata K. Horie K, Hirasawa A. Tsujimoto G. Use of recombinant a-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur JPharmacol 1995: 288: 201-7
28. Chappie CR. Couldwell CJ. Noble AJ, Chess-Williams R. The in vitro x-adrenoceptor mediated effects of tamsulosin on the human prostate. Proceedings of the 23rd Congress Société Internationale d'Urologie, Sydney, 18-22 Sept 1994: 210(A487)
29. Kawabe K. Ueno A. Takimoto Y et al. Use of an a-blocker. YM617. in the treatment of benign prostatic hypertrophy. J Urol 1990; 144: 908-12
30. Chappie CR. Wyndaele JJ. Nordling J, Boeminghaus F. Ypma AFGVM. Abrams P. Tamsulosin, the first prostateselective alx-adrenoceptor antagonist. Eur Urol 1996; 29: 155-67
31. Lepor H for the Tamsulosin Investigator Group. Clinical evaluation of tamsulosin, a prostate selective ot-lcantagonist. J Urol 1995; 153: 274 (abstract 182)